Exelixis, Inc. 10-Q Summary: Quarter Ended June 29, 2007
Business Context and Reporting Period
Exelixis, Inc. is a biopharmaceutical company focused on discovering and developing small molecule therapies for cancer and other serious diseases. This report covers the quarterly period ended June 29, 2007 (referred to as June 30, 2007 in financial tables). The company operates primarily through drug discovery and development, supplemented by a German subsidiary, Artemis Pharmaceuticals, which provides transgenic mouse generation services. Exelixis relies heavily on collaboration agreements with major pharmaceutical partners, including GlaxoSmithKline, Bristol-Myers Squibb, and Genentech, for funding and commercialization.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2007 | Six Months Ended June 30, 2007 | Balance Sheet (June 30, 2007) |
|---|---|---|---|
| Total Revenues | $29,259 | $57,395 | - |
| Net Loss | $(28,562) | $(52,763) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.29) | $(0.55) | - |
| Cash and Cash Equivalents | - | - | $105,607 |
| Total Cash, Equivalents, and Marketable Securities | - | - | $253,000 (approx.) |
| Working Capital | - | - | $125,064 |
| Total Debt (Notes, Bank Obligations, Convertible Loans) | - | - | $115,341 |
| Accumulated Deficit | - | - | $(758,032) |
Note: Total cash, equivalents, and marketable securities includes $44.7 million held by Symphony Evolution, Inc. (SEI) and $8.9 million in restricted cash.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 7% for the quarter and 27% for the six-month period compared to the prior year. This was driven by increased amortization of upfront payments from new collaborations with Bristol-Myers Squibb and Genentech, as well as higher research and development service fees.
- Expense Increases: Research and development (R&D) expenses rose 19% for the quarter and 22% for the six-month period. Increases were attributed to expanded personnel, higher clinical trial activity (Phase 1 and Phase 2), and increased lab supplies. General and administrative expenses increased 12% and 18% respectively, driven by personnel and stock-based compensation.
- Net Loss: Net loss increased to $28.6 million for the quarter and $52.8 million for the six-month period, compared to $24.0 million and $51.1 million in the prior year periods. The increase in net loss was partially offset by a higher loss attributed to the noncontrolling interest in SEI ($7.5 million for the quarter vs. $5.8 million prior year).
- Cash Flow: Net cash used in operating activities improved significantly to $4.5 million for the six months ended June 30, 2007, compared to $21.2 million in the prior year, largely due to increases in deferred revenue from collaborators.
Guidance, Outlook, and Risks
Recent Developments: On July 26, 2007, GlaxoSmithKline (GSK) announced it would not exercise its option to develop and commercialize Exelixis's compound XL647 at clinical proof-of-concept. Exelixis retains the right to develop XL647 independently or with third parties, subject to obligations with SEI. GSK retains a 3% royalty right on net sales of XL647.
Liquidity and Capital Resources: Management anticipates that current cash, marketable securities, and expected collaborator funding will support operations for at least 12 months. However, substantial additional funding will be required for future clinical development. The company must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million to comply with financial covenants in its loan agreement with GSK.
Key Risks and Contingencies:
- SEI Repurchase Option: Exelixis has an exclusive option to reacquire three compounds (XL647, XL999, XL784) from SEI. If GSK selects any of these for development, Exelixis must repurchase all three. The purchase price is $80 million plus 25% annual interest. Failure to fund this repurchase could breach the GSK agreement.
- Clinical Trial Risks: XL999 development faces uncertainty due to previous cardiovascular adverse events, leading to a partial clinical hold. A new Phase 1 protocol was accepted by the FDA, but future results remain uncertain.
- Dependence on Partners: The company has no approved products and relies on milestone payments and royalties from partners for revenue. Delays in partner milestones or termination of agreements could severely impact financial stability.
Investor Verification Checklist
- Verify the status of the XL999 clinical trial following the FDA's acceptance of the new Phase 1 protocol and any new safety data.
- Monitor the company's cash burn rate and ability to meet the $25 million working capital and $50 million cash/investment covenants with GlaxoSmithKline.
- Assess the financial implications of the SEI repurchase option, specifically the potential need to raise capital to repurchase XL647, XL999, and XL784 if GSK selects them or if Exelixis chooses to proceed independently.
- Review the impact of GSK's decision not to exercise the XL647 option on future milestone revenue projections and the company's strategic plan for XL647.
- Confirm the timeline and budget for the Phase 2 trials of XL784, XL880, and XL647, which are driving the increase in R&D expenses.